Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05974410 Available - Breast Cancer Clinical Trials

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Start date: n/a
Phase:
Study type: Expanded Access

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT05612191 Available - Gynecologic Cancer Clinical Trials

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Start date: n/a
Phase:
Study type: Expanded Access

Catequentinib (AL3818, Anlotinib) has been developed in a variety of clinical studies as single agents or in combination with others. This trial is designed to offer patients who completed an Advenchen sponsored AL3818 related study without progression the opportunity to continue to receive this investigational product in this Post-Trial Access study (a compassionate use trial), if the Investigator believes the patients can benefit from such a treatment and the patients have signed the Informed Consent Form.

NCT ID: NCT04091295 Available - Pancreatic Cancer Clinical Trials

Expanded Access for DeltaRex-G for Osteosarcoma, Chondrosarcoma, Soft Tissue Sarcoma, Pancreas and Breast Cancer

Start date: n/a
Phase:
Study type: Expanded Access

Forty patients with osteosarcoma, chondrosarcoma, soft tissue sarcoma, pancreas and breast cancer will receive DeltaRex-G intravenously at a dose of 1-4 x 10e11 colony forming units (cfu) or equivalent 0.6-1.8 x 10e10 RV copies per dose one to three times a week. DeltaRex-G may be given alone or with one or more FDA approved cancer therapies/immunotherapies. Based on previous Phase 1/2 US based clinical studies, DeltaRex-G does not suppress the bone marrow or cause serious organ dysfunction, and enhanced immune cell trafficking in tumors may cause the tumors to appear larger or new lesions to appear on CT, PET or MRI. Further, tumor stabilization/regression/remission may occur later during the treatment period. Therefore, DeltaRex-G will be continued regardless of CT, PET or MRI results if the patient has clinical benefit and does not have symptomatic disease progression.

NCT ID: NCT03994627 Available - Soft Tissue Sarcoma Clinical Trials

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

NCT ID: NCT03493165 Available - Uterine Sarcoma Clinical Trials

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

Start date: n/a
Phase:
Study type: Expanded Access

Single patient treatment with everolimus.